PK STUDY OF ANTIRETROVIRAL THERAPY REGIMENS CONTAINING TENFOVIR AND ATAZANIVIR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项开放的、24小时、单剂量的药代动力学研究。18岁零天至24岁364天的HIV-1感染者目前正在接受FDA批准的抗逆转录病毒联合疗法(包括替诺福韦加阿特拉那韦/利托那韦和至少一种其他活性抗逆转录病毒药物)的稳定组合。这项研究的目的是测量阿扎那韦/利托那韦和替诺福韦联合用于治疗感染艾滋病毒的青少年和青年受试者时的药代动力学，并将这些研究受试者的药代动力学与已发表的成人和儿童的动力学曲线进行比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, 24-hour, single-dose pharmacokinetic study. Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days currently on a stable combination antiretroviral regimen (>/= 28 days) with FDA-approved antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and at least one other active antiretroviral drug will be offered participation. The purpose of this study is to measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects and to compare the kinetics in these study subjects with published kinetic profiles in adults and children.